YALLIG‘LANISH — PARKINSONIZMDA ICHAK VA MIYA O‘RTASIDAGI BOG‘LOVCHI BO‘G‘IN
##article.subject##:
parkinsonizm; Parkinson kasalligi; interleykin-6; fekal kalprotektin; Helicobacter pylori; ichak yallig‘lanishi; “ichak–miya” o‘qi; neyroyallig‘lanish; biomarkerlar.##article.abstract##
So‘nggi yillarda parkinsonizm patogenezida “ichak–miya” o‘qi va yallig‘lanish mexanizmlarining o‘rni bo‘yicha qiziqish ortib bormoqda. Ushbu tadqiqotning maqsadi bemorlarda lokal va sistemali yallig‘lanish markerlari — interleykin-6, fekal kalprotektin va Helicobacter pylori infeksiyasini baholashdan iborat bo‘ldi. Tadqiqotga parkinsonik buzilishlarning turli shakllariga ega bo‘lgan bemorlar jalb etildi; ularda klinik holat baholandi va yallig‘lanish markerlarining laborator ko‘rsatkichlari aniqlangan. Olingan natijalarga ko‘ra, idiopatik Parkinson kasalligida IL-6 darajasi so‘dali parkinsonizmga nisbatan sezilarli darajada yuqori ekani aniqlandi. Fekal kalprotektin ko‘rsatkichlari esa yuqori variabellikka ega bo‘lib, kasallikning kechki bosqichlari bilan bog‘liq ekani kuzatildi. H. pylori infeksiyasi asosan Parkinson kasalligi bo‘lgan bemorlarda uchradi va kasallik davomiyligi hamda motor buzilishlarining og‘irligi bilan korrelyatsiya qildi. Umuman, olingan ma’lumotlar ichak va sistemali yallig‘lanishning parkinsonizm patogenezi shakllanishidagi muhim rolini tasdiqlaydi hamda mazkur markerlardan differentsial tashhis, xavfni stratifikatsiya qilish va bemorlarni individual boshqarish uchun foydalanish istiqbollarini ko‘rsatadi.Библиографические ссылки
Wei B.-R., Li H., Zhang X. Interaction between Helicobacter pylori infection, systemic inflammation and neurodegeneration in Parkinson’s disease // Immunity & Ageing. — 2024. — Vol. 21, № 1. — P. 1–15. — DOI: 10.1186/s12979-023-00404-1.
Tufekci K.U., Meuwissen R., Genc S. Inflammation in Parkinson’s disease // Advances in Protein Chemistry and Structural Biology. — 2012. — Vol. 88. — P. 69–132. — DOI: 10.1016/B978-0-12-398314-5.00004-0.
Scalzo P., Kümmer A., Cardoso F. et al. Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with severity // Neuroscience Letters. — 2010. — Vol. 468, № 1. — P. 56–58. — DOI: 10.1016/j.neulet.2009.12.064.
Brain Sciences. The inflammatory mechanism of Parkinson’s disease: gut microbiota dysbiosis // Brain Sciences. — 2024. — Vol. 15, № 2. — Article 159. — DOI: 10.3390/brainsci15020159.
Frontiers in Medicine. Association between Helicobacter pylori infection and the risk of neurodegenerative disorders: a systematic review and meta-analysis // Frontiers in Medicine. — 2025. — Article 1573299. — DOI: 10.3389/fmed.2025.1573299.
Reale M., Iarlori C., Thomas A. et al. Peripheral cytokines profile in Parkinson’s disease patients: association with motor and non-motor symptoms // Journal of Neuroimmunology. — 2009. — Vol. 214, № 1–2. — P. 104–108. — DOI: 10.1016/j.jneuroim.2009.01.012.
Zhong R., Chen Q., Zhang T. Helicobacter pylori infection and Parkinson’s disease: a systematic review and meta-analysis // Journal of Neurology. — 2021. — Vol. 268, № 12. — P. 4594–4605. — DOI: 10.1007/s00415-021-10473-1.
Inflammopharmacology. Gut microbiota and Parkinson’s disease: a new frontier in understanding neurological health // Inflammopharmacology. — 2025. — DOI: 10.1007/s10787-025-01726-w.
Harms A.S., Kordower J.H., Zhang Y. et al. Microglial activation and neuroinflammation in Parkinson’s disease // Nature Reviews Neurology. — 2021. — DOI: 10.1038/s41582-021-00525-4.
Heinzel S., Roeben B., Ben-Shlomo Y. et al. Prodromal markers in Parkinson’s disease: limitations in longitudinal studies and lessons learned // Frontiers in Aging Neuroscience. — 2016. — Vol. 8. — Article 147. — DOI: 10.3389/fnagi.2016.00147.
Chtioui C.H.R., Duval D.A.V., St-Pierre A. Reduced intestinal inflammation and increased levels of short-chain fatty acids thanks to an active lifestyle in Parkinson’s disease // Movement Disorders. — 2024. — Vol. 39 (Suppl. 1). — Abstract № 654.
Sampson T.R., Debelius J.W., Thron T. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease // Cell. — 2016. — Vol. 167, № 6. — P. 1469–1480.e12. — DOI: 10.1016/j.cell.2016.11.018.
Houser M.C., Tansey M.G. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? // NPJ Parkinson’s Disease. — 2017. — Vol. 3. — Article 3. — DOI: 10.1038/s41531-017-0009-9.
Qin X.-Y., Zhang S.-P., Cao C., Loh Y.P., Cheng Y. Peripheral interleukin-6 levels in Parkinson’s disease: a systematic review and meta-analysis // Journal of Neurological Sciences. — 2016. — DOI: 10.1016/j.jns.2015.12.003.
Kempuraj D., Thangavel R., Selvakumar G.P. et al. Neuroinflammation in Parkinson’s Disease // Journal of Neuroimmune Pharmacology. — 2018. — DOI: 10.1007/s11481-018-9780-5.
Zijlmans J.C.M., Daniel S.E., Hughes A.J. et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis // Movement Disorders. — 2004. — Vol. 19, № 6. — P. 630–640. — DOI: 10.1002/mds.20025.
Kalaria R.N., Perry R.H. Vascular Parkinsonism: pathology and mechanisms // Acta Neuropathologica. — 2013. — Vol. 125, № 1. — P. 1–18. — DOI: 10.1007/s00401-013-1087-3.
McColl B.W., Allan S.M., Rothwell N.J. Systemic inflammation and stroke // Nature Reviews Neuroscience. — 2009. — Vol. 10, № 6. — P. 481–493. — DOI: 10.1038/nrn2648.
Dobbs R.J., Charlett A., Dobbs S.M. et al. Helicobacter hypothesis for idiopathic Parkinsonism: evidence from systemic inflammatory responses // Parkinsonism and Related Disorders. — 2008. — Vol. 14, № 6. — P. 456–463. — DOI: 10.1016/j.parkreldis.2007.08.003.
Wang T., Liu X., Huang Y. Study finds fewer Helicobacter pylori infections among Parkinson’s patients // News-Medical. — 2025. — URL:
Zhong R., Chen Q., Zhang T. Helicobacter pylori infection and Parkinson’s disease: a systematic review and meta-analysis // Journal of Neurology. — 2021. — Vol. 268, № 12. — P. 4594–4605. — DOI: 10.1007/s00415-021-10473-1.
